I stand by what I said. On a worldwide revenue basis, there are many other manufacturers that have strong incentives to develop a cure. Also, I disagree that "PrEP" would eliminate HIV. It's a prophylactic, not a cure, and one that will not be affordable globally for a looooong time. Even at $30 per month, the drug would be out of reach for many (see Africa where annual incomes hover around $1-2K annually.)

1. Gilead owns 3 of 4 top HIV drugs. GSK owns the #2, Triumeq.

2. GSK, Merk, J&J are all megacap, viable competitors with their own HIV products. Yes, its true that Merk and Gilead are in cahoots, but this was out of fear of GSKs dominance.

3. Some other US-listed names who are developing HIV drugs: ViiV (GSK subsidiary), Bristol Myers Squibb, Janssen, Mylan, Genentech, Abbvie.

Yes, the US is currently dominated by one company, but that does not mean there are heavy incentives for competitors--who are already well invested in the space--to break in.

[0]: https://www.statista.com/statistics/273434/revenue-of-the-wo...